MYC is altered in 12.93% of diffuse large B-cell lymphoma patients with MYC Mutation present in 10.04% of all diffuse large B-cell lymphoma patients [4].

MYC Mutation is an inclusion criterion in 4 clinical trials for diffuse large B-cell lymphoma, of which 2 are open and 2 are closed. Of the trials that contain MYC Mutation and diffuse large B-cell lymphoma as inclusion criteria, 3 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

MYC is altered in 4.85% of malignant solid tumor patients with MYC Mutation present in 0.89% of all malignant solid tumor patients [4].

MYC Mutation is an inclusion criterion in 4 clinical trials for malignant solid tumor, of which 0 are open and 4 are closed. Of the trials that contain MYC Mutation and malignant solid tumor as inclusion criteria, 2 are phase 1 (0 open) and 2 are phase 1/phase 2 (0 open) [5].

MYC is altered in 1.82% of hodgkin lymphoma patients with MYC Mutation present in 1.82% of all hodgkin lymphoma patients [4].

MYC Mutation is an inclusion criterion in 3 clinical trials for hodgkin lymphoma, of which 2 are open and 1 is closed. Of the trials that contain MYC Mutation and hodgkin lymphoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

MYC is altered in 4.84% of non-small cell lung carcinoma patients with MYC Mutation present in 0.89% of all non-small cell lung carcinoma patients [4].

MYC Mutation is an inclusion criterion in 3 clinical trials for non-small cell lung carcinoma, of which 0 are open and 3 are closed. Of the trials that contain MYC Mutation and non-small cell lung carcinoma as inclusion criteria, 2 are phase 1 (0 open) and 1 is phase 1/phase 2 (0 open) [5].

MYC is altered in 3.39% of mantle cell lymphoma patients with MYC Mutation present in 0.56% of all mantle cell lymphoma patients [4].

MYC Mutation is an inclusion criterion in 3 clinical trials for mantle cell lymphoma, of which 2 are open and 1 is closed. Of the trials that contain MYC Mutation and mantle cell lymphoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

MYC is altered in 6.64% of non-hodgkin lymphoma patients with MYC Mutation present in 4.67% of all non-hodgkin lymphoma patients [4].

MYC Mutation is an inclusion criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain MYC Mutation and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [5].

MYC is altered in 7.33% of ovarian carcinoma patients with MYC Mutation present in 1.27% of all ovarian carcinoma patients [4].

MYC Mutation is an inclusion criterion in 2 clinical trials for ovarian carcinoma, of which 0 are open and 2 are closed. Of the trials that contain MYC Mutation and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (0 open) [5].

MYC is altered in 2.79% of follicular lymphoma patients with MYC Mutation present in 1.24% of all follicular lymphoma patients [4].

MYC Mutation is an inclusion criterion in 2 clinical trials for follicular lymphoma, of which 1 is open and 1 is closed. Of the trials that contain MYC Mutation and follicular lymphoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [5].

MYC is altered in 4.93% of colorectal carcinoma patients with MYC Mutation present in 0.97% of all colorectal carcinoma patients [4].

MYC Mutation is an inclusion criterion in 2 clinical trials for colorectal carcinoma, of which 0 are open and 2 are closed. Of the trials that contain MYC Mutation and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (0 open) [5].

MYC is altered in 1.9% of multiple myeloma patients with MYC Mutation present in 0.95% of all multiple myeloma patients [4].

MYC Mutation is an inclusion criterion in 2 clinical trials for multiple myeloma, of which 1 is open and 1 is closed. Of the trials that contain MYC Mutation and multiple myeloma as inclusion criteria, 2 are phase 1 (1 open) [5].

MYC is altered in 9.92% of breast carcinoma patients with MYC Mutation present in 0.58% of all breast carcinoma patients [4].

MYC Mutation is an inclusion criterion in 2 clinical trials for breast carcinoma, of which 0 are open and 2 are closed. Of the trials that contain MYC Mutation and breast carcinoma as inclusion criteria, 2 are phase 1 (0 open) [5].

MYC Mutation is an inclusion criterion in 2 clinical trials for chronic lymphocytic leukemia, of which 2 are open and 0 are closed. Of the trials that contain MYC Mutation and chronic lymphocytic leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

MYC Mutation is an inclusion criterion in 2 clinical trials for double-hit lymphoma, of which 1 is open and 1 is closed. Of the trials that contain MYC Mutation and double-hit lymphoma as inclusion criteria, 2 are phase 1 (1 open) [5].

MYC is altered in 64.29% of Burkitt lymphoma patients with MYC Mutation present in 50.0% of all Burkitt lymphoma patients [4].

MYC Mutation is an inclusion criterion in 1 clinical trial for Burkitt lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYC Mutation and Burkitt lymphoma as inclusion criteria, 1 is phase 1 (0 open) [5].

MYC is altered in 14.29% of vaginal carcinoma patients with MYC Mutation present in 14.29% of all vaginal carcinoma patients [4].

MYC Mutation is an inclusion criterion in 1 clinical trial for vaginal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MYC Mutation and vaginal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

MYC is altered in 7.91% of B-cell non-hodgkin lymphoma patients with MYC Mutation present in 5.57% of all B-cell non-hodgkin lymphoma patients [4].

MYC Mutation is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MYC Mutation and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MYC is altered in 7.91% of mature B-cell non-hodgkin lymphoma patients with MYC Mutation present in 5.57% of all mature B-cell non-hodgkin lymphoma patients [4].

MYC Mutation is an inclusion criterion in 1 clinical trial for mature B-cell non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYC Mutation and mature B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) [5].

MYC is altered in 5.87% of lymphoma patients with MYC Mutation present in 4.11% of all lymphoma patients [4].

MYC Mutation is an inclusion criterion in 1 clinical trial for lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYC Mutation and lymphoma as inclusion criteria, 1 is phase 1 (0 open) [5].

MYC is altered in 3.51% of bladder carcinoma patients with MYC Mutation present in 1.57% of all bladder carcinoma patients [4].

MYC Mutation is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MYC Mutation and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

MYC is altered in 4.77% of melanoma patients with MYC Mutation present in 1.51% of all melanoma patients [4].

MYC Mutation is an inclusion criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains MYC Mutation and melanoma as inclusion criteria, 1 is phase 1 (0 open) [5].

MYC is altered in 1.9% of anal carcinoma patients with MYC Mutation present in 1.27% of all anal carcinoma patients [4].

MYC Mutation is an inclusion criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MYC Mutation and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

MYC is altered in 3.77% of cervical carcinoma patients with MYC Mutation present in 1.26% of all cervical carcinoma patients [4].

MYC Mutation is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MYC Mutation and cervical carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

MYC is altered in 8.24% of high grade ovarian serous adenocarcinoma patients with MYC Mutation present in 1.08% of all high grade ovarian serous adenocarcinoma patients [4].

MYC Mutation is an inclusion criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains MYC Mutation and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

MYC is altered in 2.64% of head and neck carcinoma patients with MYC Mutation present in 0.96% of all head and neck carcinoma patients [4].

MYC Mutation is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MYC Mutation and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

MYC is altered in 1.61% of glioblastoma patients with MYC Mutation present in 0.93% of all glioblastoma patients [4].

MYC Mutation is an inclusion criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains MYC Mutation and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [5].

MYC is altered in 1.76% of mature T-cell and NK-cell non-hodgkin lymphoma patients with MYC Mutation present in 0.88% of all mature T-cell and NK-cell non-hodgkin lymphoma patients [4].

MYC Mutation is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MYC Mutation and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MYC is altered in 5.87% of prostate carcinoma patients with MYC Mutation present in 0.86% of all prostate carcinoma patients [4].

MYC Mutation is an inclusion criterion in 1 clinical trial for prostate carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MYC Mutation and prostate carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

MYC is altered in 1.5% of papillary renal cell carcinoma patients with MYC Mutation present in 0.75% of all papillary renal cell carcinoma patients [4].

MYC Mutation is an inclusion criterion in 1 clinical trial for papillary renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MYC Mutation and papillary renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

MYC is altered in 2.32% of head and neck squamous cell carcinoma patients with MYC Mutation present in 0.74% of all head and neck squamous cell carcinoma patients [4].

MYC Mutation is an inclusion criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MYC Mutation and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

MYC is altered in 1.36% of chronic lymphocytic leukemia/small lymphocytic lymphoma patients with MYC Mutation present in 0.51% of all chronic lymphocytic leukemia/small lymphocytic lymphoma patients [4].

MYC Mutation is an inclusion criterion in 1 clinical trial for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MYC Mutation and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MYC is altered in 2.52% of soft tissue sarcoma patients with MYC Mutation present in 0.46% of all soft tissue sarcoma patients [4].

MYC Mutation is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains MYC Mutation and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

MYC is altered in 0.7% of gastrointestinal stromal tumor patients with MYC Mutation present in 0.42% of all gastrointestinal stromal tumor patients [4].

MYC Mutation is an inclusion criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 0 are open and 1 is closed. Of the trial that contains MYC Mutation and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1 (0 open) [5].

MYC is altered in 0.62% of pleural mesothelioma patients with MYC Mutation present in 0.41% of all pleural mesothelioma patients [4].

MYC Mutation is an inclusion criterion in 1 clinical trial for pleural mesothelioma, of which 0 are open and 1 is closed. Of the trial that contains MYC Mutation and pleural mesothelioma as inclusion criteria, 1 is phase 1 (0 open) [5].

MYC is altered in 3.1% of sarcoma patients with MYC Mutation present in 0.37% of all sarcoma patients [4].

MYC Mutation is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains MYC Mutation and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [5].

MYC is altered in 3.79% of pancreatic carcinoma patients with MYC Mutation present in 0.32% of all pancreatic carcinoma patients [4].

MYC Mutation is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MYC Mutation and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

MYC is altered in 0.8% of renal cell carcinoma patients with MYC Mutation present in 0.29% of all renal cell carcinoma patients [4].

MYC Mutation is an inclusion criterion in 1 clinical trial for renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MYC Mutation and renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

MYC is altered in 2.53% of anaplastic astrocytoma patients with MYC Mutation present in 0.28% of all anaplastic astrocytoma patients [4].

MYC Mutation is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 0 are open and 1 is closed. Of the trial that contains MYC Mutation and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (0 open) [5].

MYC is altered in 0.68% of clear cell renal cell carcinoma patients with MYC Mutation present in 0.14% of all clear cell renal cell carcinoma patients [4].

MYC Mutation is an inclusion criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MYC Mutation and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

MYC Mutation is an inclusion criterion in 1 clinical trial for hairy cell leukemia, of which 1 is open and 0 are closed. Of the trial that contains MYC Mutation and hairy cell leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MYC Mutation is an inclusion criterion in 1 clinical trial for intraocular lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MYC Mutation and intraocular lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MYC Mutation is an inclusion criterion in 1 clinical trial for lymphoplasmacytic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MYC Mutation and lymphoplasmacytic lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MYC Mutation is an inclusion criterion in 1 clinical trial for marginal zone lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MYC Mutation and marginal zone lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MYC Mutation is an inclusion criterion in 1 clinical trial for mature B-cell lymphoma/leukemia, of which 1 is open and 0 are closed. Of the trial that contains MYC Mutation and mature B-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MYC is altered in 4.17% of penile carcinoma patients [4].

MYC Mutation is an inclusion criterion in 1 clinical trial for penile carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MYC Mutation and penile carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

MYC Mutation is an inclusion criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYC Mutation and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [5].

MYC Mutation is an inclusion criterion in 1 clinical trial for peritoneal mesothelioma, of which 0 are open and 1 is closed. Of the trial that contains MYC Mutation and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (0 open) [5].

MYC Mutation is an inclusion criterion in 1 clinical trial for plasma cell leukemia, of which 1 is open and 0 are closed. Of the trial that contains MYC Mutation and plasma cell leukemia as inclusion criteria, 1 is phase 1 (1 open) [5].

MYC Mutation is an inclusion criterion in 1 clinical trial for small intestinal lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MYC Mutation and small intestinal lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MYC Mutation is an inclusion criterion in 1 clinical trial for small lymphocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains MYC Mutation and small lymphocytic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MYC Mutation is an inclusion criterion in 1 clinical trial for small lymphocytic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MYC Mutation and small lymphocytic lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MYC Mutation is an inclusion criterion in 1 clinical trial for triple-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MYC Mutation and triple-hit lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MYC Mutation is an inclusion criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MYC Mutation and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].